Severe Acute Respiratory Syndrome (SARS) Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017 provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Severe Acute Respiratory Syndrome (SARS) - Overview
  3. Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
  • 3-V Biosciences Inc
  • Atriva Therapeutics GmbH
  • Autoimmune Technologies LLC
  • CEL-SCI Corp
  • Fab'entech SA
  • GeneCure LLC
  • Gilead Sciences Inc
  • Nanotherapeutics Inc
  • Novavax Inc
  • Oncovir Inc
  • Phelix Therapeutics LLC
  • Protein Sciences Corp

For more information about this report visit https://www.researchandmarkets.com/research/5vwqqj/severe_acute

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs